Sign In
Buy MNKD
$4.13
+0.240 (+6.17%)
At Close: Jul 24, 2026
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
02:06pm, Friday, 24'th Jul 2026
Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U.S. Food and Drug Administration's (FDA) approval of Furoscix ReadyFlow, an at-home treatment option
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
11:05am, Friday, 24'th Jul 2026
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds
MannKind Announces $50 Million Private Placement
06:35am, Friday, 24'th Jul 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema
What This MannKind Filing Reveals About Three Years of Underperformance
07:24pm, Monday, 20'th Jul 2026
This MannKind insider filing details the disposition of 46,795 shares. The transaction reduced the insider's direct equity holdings by 9%.
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
07:16pm, Monday, 20'th Jul 2026
The transactions involved 76,880 shares with a total value of about $313,000, based on a weighted average execution price of $4.07 per share. The disposition represented 9% of direct common stock hold
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million
07:05pm, Monday, 20'th Jul 2026
David Thomson disposed of 123,000 shares at $4.08 per share, representing a total transaction value of about $500,000. The activity resulted in a 13% decrease in direct common stock holdings, which in
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk
06:55pm, Monday, 20'th Jul 2026
This filing reported an insider's total disposition of 65,808 shares for an estimated value of $269,000 based on the July 15, 2026 market close. The transaction represented 6% of the insider's total d
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?
08:48pm, Sunday, 19'th Jul 2026
The disposition involved ~363,000 shares valued at ~$1.5 million as of the July 15, 2026 transaction date. The activity represents 13% of the executive's direct equity holdings in the company.
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize p
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
10:40pm, Tuesday, 02'nd Jun 2026
MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza's pediatric label extension as
